Abstract: A unitary elastomeric structure comprising: an annular body having an inward facing annular channel formed in an upper portion of the body and an annular sealing structure formed in a lower portion of the body, wherein the annular sealing structure is concentric with and radially within the annular channel; and a plurality of grommets disposed radially around and integrally formed with the annular body, wherein each grommet has opposing upper and lower surfaces and a bore extending through the grommet between the upper and lower surfaces.

Abstract: A method for measuring gut permeability includes administering a solution including a fluorescent contrast agent to a subject; irradiating a location on the skin of the subject to cause a portion of the solution leaked into the bloodstream to fluoresce; obtaining fluorescence data of the intensity of the fluorescence as a function of time; normalising the fluorescence data to obtain normalised data of said intensity as a function of time; and analysing said normalised data to determine the gut permeability by calculating: (a) the first peak value of said intensity; (b) the integral of said intensity with respect to time; (c) the product of the first peak value of said intensity and the time at said peak value; (d) the time at which the first peak value of said intensity occurs; or (e) the first peak value of said intensity divided by the time at which said peak value occurs.

Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.

Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.

Abstract: The present invention provides genetic markers and biomarkers that are associated with anemia induced by ribavirin therapy. The genetic markers are located in the ITPA gene and elsewhere on human chromosome 20 and the biomarkers are low ITPA activity phenotypes. These markers of ribavirin-induced anemia are useful, inter alia, to identify patients who are least likely to develop anemia upon treatment with ribavirin pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with ribavirin, and in methods for selecting the most appropriate therapy for such patients.

Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers arc useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.